Trial
NCT05006573
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Non-cystic Fibrosis Bronchiectasis
Intervention
Benralizumab
Why stopped
Due to the decision to stop recruitment early, enrolment into the MAHALE trial was terminated in August 2022; 139 patients were screened and 100 randomised to IP.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-20